07:00 , Aug 20, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Conversion of rhesus D (RhD)-positive to RhD-negative blood type via genome editing

Drug platforms TECHNOLOGY: Cell therapy Deletion of the RhD gene via genome editing could convert RhD-positive erythrocytes into RhD-negative cells for blood donations. In an RhD-positive human erythroid progenitor cell line, transcription activator-like effector nucleases...
07:00 , May 6, 2013 |  BioCentury  |  Finance

Symphogen stocks up

After topping up its coffers last week, Symphogen A/S now has the cash and long-term investor base to see the Danish antibody platform play through its goal of building out a pipeline and taking at...
07:00 , Aug 27, 2012 |  BC Week In Review  |  Clinical News

Rozrolimupab: Final Phase II data

Previously reported data from a dose-escalation, open-label, international Phase II trial of rozrolimupab in 61 RhD-positive, non-splenectomized patients with ITP were published in Blood. The data showed that a single IV infusion of 300 ug/kg...
08:00 , Jan 9, 2012 |  BC Week In Review  |  Clinical News

Rozrolimupab: Final Phase II data

Final data from a dose-escalation, open-label, international Phase II trial in 61 Rhesus D (RhD)-positive, non-splenectomized patients with ITP showed that a single dose of 300 µg/kg IV Sym001 produced a response rate of 62%...
07:00 , Jun 27, 2011 |  BC Week In Review  |  Clinical News

Rozrolimupab: Phase II data

A dose-escalation, open-label Phase II trial in 38 evaluable Rhesus D (RhD)-positive, non-splenectomized patients with ITP showed that 75, 100, 125, 150 and 200 µg/kg doses of IV Sym001 produced response rates of 0%, 70%,...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Clinical News

SensiGene Fetal RHD Genotyping test diagnostic data

In a serotype reference cohort consisting of 207 samples of circulating cell-free fetal DNA extracted from maternal plasma during the first trimester of pregnancy, Sequenom's SensiGene RHD Genotyping test had 97.2% sensitivity and 96.8% specificity...
07:00 , Apr 12, 2010 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/9 cls Actelion Ltd. (SIX:ATLN) UBS Martin Wales Upgrade Buy (from neutral) 3% CHF49.85 Wales said he thinks the shares have been oversold since...
07:00 , Mar 22, 2010 |  BioCentury  |  Finance

Scared off Sequenom

Sequenom Inc. (NASDAQ:SQNM) shareholders got cold feet last week after the company said on its earnings call that it will need to raise money this year - and that it will not necessarily wait for...
08:00 , Mar 8, 2010 |  BioCentury  |  Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes Company Bank Analyst Coverage Opinion Wk chg 3/5 cls Actelion Ltd. (SIX:ATLN) Jefferies Peter Welford Price target Buy -13% CHF47.80 Welford lowered his target to CHF73 from CHF90 after Tracleer bosentan...
08:00 , Feb 22, 2010 |  BC Week In Review  |  Company News

Sequenom sales and marketing update

Sequenom launched its SensiGene Fetal(XY) test to determine the sex of the fetus during the first trimester of pregnancy. The test, which detects circulating cell-free fetal DNA in maternal blood, runs on Sequenom's MassARRAY platform...